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Solving the Structure of eIF2 Bound to eIF2B Using Cryogenic Electron Microscopy 
 
by 
 
Lillian Rose Kenner 
 
 
Abstract 
 
Translation begins when initiation factor-2 (eIF2) delivers methionyl initiator tRNA 
(Met-tRNAi) to the ribosome. The exchange of GDP bound to eIF2 for GTP is a prerequisite to 
binding Met-tRNAi and is mediated by a second initiation factor, eIF2B. Regulation of mRNA 
translation is achieved through phosphorylation of eIF2 α at Ser51 which converts eIF2 from a 
substrate into a competitive inhibitor of eIF2B. Using the latest cryo-electron microscopy 
(cryoEM) technologies in both collection and data processing we were able to obtain three high 
resolution structures to interrogate the structural basis of the integrated stress response. 
Here we discuss the structures of eIF2 bound to eIF2B as well as two eIF2s bound to 
eIF2B, and S51 phosphorylated eIF2α bound to eIF2B. These structures were determined to 
fulfill these two goals, 1) how eIF2 binds to eIF2B for productive nucleotide exchange; and 2) 
how ISR-driven phosphorylation of eIF2 changes its binding. 
The three structures discussed here have been solved by cryoEM. CryoEM is a high 
resolution technique for visualizing radiation-sensitive specimens like biological 
macromolecules. Recent advances of cryo-EM are provided by two major innovations. One is the 
employment of direct electron detector which can detect electrons directly and read them at high 
frame rate without a mechanical shutter. The other is motion correction, which compensates for 
the blurring effect of beam-induced motion. These two technologies have led to a “resolution 
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revolution” in cryoEM. Utilizing the most up to date software and hardware available through 
UCSF we were able to solve the structures of three protein complexes which were previously 
unattainable. 
The first two structures of non-phosphorylated eIF2 bound to eIF2B reveal the 
mechanism for nucleotide turnover of eIF2. Similar to other G proteins, eIF2 switches between 
active GTP and inactive GDP bound states. Each round of nucleotide exchange of GDP to GTP 
on eIF2 by eIF2B reinitiates the eIF2 cycle that is essential for continued protein translation. The 
structural requirements of how eIF2B exchanges nucleotide on eIF2 have never been fully 
described. Here we observe that the two faces of eIF2Bε splay open the eIF2γ GTP/GDP binding 
site allowing GDP release. Given the lack of direct interaction between the HEAT domain of 
eIF2Bε with the relevant areas of nucleotide exchange of the eIF2γ subunit, we proposed that G 
domain nucleotide exchange is modulated through an allosteric interaction with the HEAT 
domain. C-terminal of the HEAT domain, eIF2Bε core at N258 and D262 binds the P-Loop of 
eIF2γ through electrostatic contacts with R75. 
The third structure is of S51 phosphorylated eIF2α bound to eIF2B. Here we propose the 
mechanistic basis of how phosphorylation converts eIF2 from substrate to inhibitor of eIF2B. In 
eIF2αP, the rearrangement of the S-loop derives from an intramolecular electrostatic interaction 
between Arg63 and Arg53 and the phosphate, which also exposes a hydrophobic surface upon 
phosphorylation-induced refolding. Through these interactions eIF2α-P adopts a new 
conformation which suggests how the S-loop may become incompatible for binding to the site 
where non-phosphorylated eIF2α binds as a substrate. This new binding mode is nonproductive 
for nucleotide exchange on eIF2-P and likely sequesters the catalytic domains into an inhibited 
v  
state that prevents the catalytic moieties of eIF2Bε from properly engaging in productive 
nucleotide exchange. 
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Abstract 
 
The integrated stress response (ISR) tunes the rate of protein synthesis. Control is exerted 
by phosphorylation of the general translation initiation factor eIF2. eIF2 is a guanosine 
triphosphatase that becomes activated by eIF2B, a two-fold symmetric and heterodecameric 
complex that functions as eIF2’s dedicated nucleotide exchange factor. Phosphorylation converts 
eIF2 from a substrate into an inhibitor of eIF2B. We report cryo–electron microscopy structures 
of eIF2 bound to eIF2B in the dephosphorylated state.The structures reveal that the eIF2B 
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decamer is a static platform upon which one or two flexible eIF2 trimers bind and align with 
eIF2B’s bipartite catalytic centers to catalyze nucleotide exchange. Phosphorylation refolds 
eIF2a, allowing it to contact eIF2B at a different interface and, we surmise, thereby sequestering 
it into a nonproductive complex. 
 
 
Introduction 
 
Numerous factors regulate translation of the genetic code into proteins, including 
eukaryotic translation initiation factor 2 (eIF2), a guanosine triphosphatase (GTPase) composed 
of a, b, and g subunits. During initiation, eIF2 binds tRNAMet and GTP to form a ternary 
complex that scans mRNAs for start codons. After start codon detection, eIF2g hydrolyzes its 
GTP and translation initiates. For eIF2 reactivation, guanosine diphosphate (GDP) is replaced by 
GTP upon catalysis by a dedicated guanine nucleotide exchange factor (GEF), eIF2B. eIF2 and 
eIF2B control translation initiation. Stress-responsive kinases phosphorylate eIF2a at the 
conserved residue Ser51, transforming eIF2 from substrate into a competitive GEF inhibitor. 
Phosphoregulation of eIF2 is known as the integrated stress response (ISR) (1). Once activated, 
the ISR reduces overall protein synthesis while enhancing translation of a small subset of 
mRNAs in response to cellular threats, including protein misfolding, infection, inflammation, 
and starvation (1–3). eIF2B comprises two copies each of an a, b, g, d, and e subunit that 
assemble into a two-fold symmetric heterodecamer (4, 5). The eIF2Be subunit contains the 
enzyme’s catalytic center and associates closely with eIF2Bg. Two copies each of the eIF2Bb 
and eIF2Bd subunits form the complex’s core, bridged by two eIF2Ba subunits across the 
symmetry interface (4, 6). Genetic and biochemical studies have identified residues responsible 
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for eIF2B’s catalytic activity and have suggested how eIF2 binding to eIF2B may differ after 
eIF2a Ser51 phosphorylation (4, 7–10). Yet it has remained unknown how eIF2 recognizes 
eIF2B, how eIF2B catalyzes nucleotide exchange, or how eIF2 transforms from a substrate to a 
high-affinity inhibitor of eIF2B after its phosphorylation. A potent small-molecule, drug-like 
inhibitor of the integrated stress response, ISRIB, allays the effects of eIF2a phosphorylation by 
activating eIF2B (11–13). Upon adding ISRIB, cells undergoing the ISR resume translation 
(12, 13). When administered to rodents, ISRIB enhances cognition and ameliorates cognitive 
deficits caused by traumatic brain injury and prioninduced neurodegeneration (15). 
Furthermore, eIF2B activation rescues cognitive and motor function in mouse models of 
leukoencephalopathy with vanishing white matter disease (VWMD), a fatal familial disorder 
associated with mutations spread over all eIF2B subunits (16). ISRIB bridges the symmetric 
interface of two eIF2B subcomplexes to enhance the formation of the decameric eIF2B 
holoenzyme (17, 18), enhancing available GEF activity by promoting higher-order assembly of 
the eIF2B decamer. However, it has remained an enigma why decameric eIF2B would be more 
active than its unassembled subcomplexes. To explore this question, we determined structures 
of eIF2B bound with both its substrate, eIF2 (a,b,g), and its inhibitor, eIF2a•P. 
 
 
Results 
 
eIF2B heterodecamer bound to one or two eIF2 heterotrimers 
 
We coexpressed all five subunits of human eIF2B in Escherichia coli and all three 
subunits of human eIF2 in Saccharomyces cerevisiae (fig. S1, A and B). The yeast expression 
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strain lacked GCN2, an eIF2 kinase, to ensure expression of homogeneously nonphosphorylated 
eIF2 (19). We incubated ISRIB and purified eIF2 at concentrations near the Michaelis constant 
of the nucleotide exchange reaction [Km = ~1.5 mM (17)] and added an inter-amine cross-linker 
to stabilize complexes before sample vitrification and cryo– electron microscopy (cryo-EM) 
analysis (fig. S2, A to C). We resolved two structures: eIF2B bound asymmetrically to a single 
eIF2 trimer and eIF2B bound symmetrically to two eIF2 trimers (Fig. 1, figs. S3A, S4, and S5, 
and tables S1 to S3). Snaking across the surface of eIF2B, we observed density consistent in size 
and shape with eIF2 subunits and the previously unresolved eIF2Be HEAT domain. Comparison 
with homologous structures of eIF2a and eIF2g revealed that the assembled eIF2•eIF2B complex 
retained similarity to the structures of these individually analyzed domains (20–22) (Fig. 2 and 
fig. S6). We resolved only a single helix of eIF2b (Fig. 1, A and D, and Fig. 2A), consistent with 
other studies (20, 21). In both reconstructions, all five subunits of eIF2B can be superimposed on 
previously determined structures lacking eIF2 [root mean square deviation (RMSD) ≈ 0.6 Å] 
(17). Thus, eIF2B retained its overall arrangement when bound to one or two eIF2s (Fig. 1), 
indicating that eIF2 binds via equivalent modes to both sides of a static eIF2B scaffold with no 
allostery in eIF2B upon eIF2 engagement. This is consistent with noncooperative kinetics 
reported for nucleotide exchange by eIF2B decamers (17). 
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Fig. 1 eIF2B heterodecamer bound to one or two eIF2 heterotrimers. 
(A to C) Orthogonal views of a single elongated eIF2 heterotrimer bound to ISRIB-stabilized 
eIF2B decamers. ISRIB density is rendered in white. (D to F) Orthogonal views of a pair of 
elongated eIF2 heterotrimers bound to ISRIB-stabilized eIF2B decamers. ISRIB density is 
rendered in white. 
 
 
Bound to eIF2B, eIF2 adopted an extended 150 Å conformation (Figs. 1 and 2A) with 
eIF2’s central nucleotide-binding g subunit flanked by its a and b subunits at its opposing ends. 
eIF2g contains classical GTP-binding motifs, including the nucleobase-binding G4 motif, the 
phosphatebinding P-loop, and switch helices 1 and 2. eIF2B recognizes eIF2 via coincident 
binding of both eIF2a and eIF2g. Binding to both eIF2 subunits involves bipartite elements of 
eIF2B (Fig. 1 and Fig. 2, A to C). 
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Fig. 2 The bipartite basis of guanine nucleotide exchange by eIF2B. 
(A) Structural model of a single eIF2 heterotrimer bound to the eIF2B decamer, emphasizing the 
cryo-EM density for eIF2γ and its interactions with eIF2Bε. (B) Switch 1 of eIF2γ stabilized as 
an open loop due to interactions between R75 eIF2γ and Q258 and D262 of eIF2Bε. (C) Y583 
from the HEAT domain of eIF2Bε (one helix shown) contacting eIF2γ E172. (D and E) 
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Comparison of the open, nucleotide-free state of eIF2 reported here (D) and an aIF2 structure 
bound to GTP (PDB: 4RCY) (E). Amino acid abbreviations: D, Asp; E, Glu; Q, Gln; R, Arg; Y, 
Tyr. 
 
 
First, bipartite recognition of eIF2g involves two domains of eIF2Be that function 
together to splay open the nucleotide-binding site. Our nucleotide-free cryo-EM model is similar 
to the g subunit of GTP-bound aIF2 from Sulfolobus solfataricus (23) (Fig. 2, D and E; average 
RMSD ≈ 2.3 Å). However, surrounding the GTP-binding pocket, the structures diverged 
considerably, with the P-loop in eIF2B•eIF2 partially occluding the nucleotide-binding site 
(RMSD ≈ 12 Å). Prior work implicated the HEAT domain in catalysis (23–26). In agreement 
with those findings, eIF2g interacts with the HEAT domain, including a partially hydrophobic 
surface that includes eIF2Be Tyr583 (Fig. 2C). On the opposing side of the nucleotide-binding 
pocket, the central core of eIF2Be engaged with an open-loop conformation of switch 1. This 
change appears to be due to electrostatic interactions between eIF2g Arg75 in switch 1 and 
Gln258 and Asp262 in eIF2Be (Fig. 2B). Thus, both eIF2Be’s HEAT domain and core 
collaborate to open the nucleotidebinding site (Fig. 2, B to D). The second example of bipartite 
recognition concerns eIF2a binding in the cleft between eIF2Bb and eIF2Bd′ (d′ denotes the d 
subunit) Notably, this binding site only exists when two tetramers of eIF2B (bgde) associate to 
form the symmetry interface in octameric eIF2B (bgde)2. eIF2a contains two structured domains 
separated by a flexible linker (Figs. 1 and 2 and fig. S6). 
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The bipartite basis of eIF2a recognition and assembly-stimulated activity 
 
The N terminus consists of an OB-fold, common in tRNA-binding proteins (20). The 
OB-fold is further elaborated with a positively charged loop (the S-loop), while the C-terminal 
ab-fold connects eIF2a to eIF2g. The S-loop harbors Ser51 and is responsible for all of the 
resolvable contacts between eIF2a and eIF2B’s b subunit (Fig. 3A). Prior work implicated a 
conserved “ 79KGYID83” (Lys79-Gly80-Tyr81-Ile82-Asp83) motif in eIF2a as being important 
for eIF2B binding (10). Of note, an interaction between Tyr81 was well resolved adjacent to the 
equally prominent Arg250 on eIF2Bd′ (Fig. 3B). When we mutated Arg250 to either alanine 
(R250A) or glutamate (R250E), neither mutation affected the residual GEF activity displayed by 
dissociated tetramers (Fig. 3D; R250A kobs = 0.013 min−1 , R250E kobs = 0.023 min−1 , wild- 
type kobs = 0.016 min−1 ), whereas both mutants diminished the GEF activity of the ISRIB- 
stabilized eIF2B octamer when compared to the wild type (Fig. 3E; R250A kobs = 0.012 min−1 , 
R250E kobs =0.017 min−1 ,wild-type kobs = 0.063 min−1 ). This is consistent with the notion 
that unphosphorylated eIF2a interacts with the trans tetramer only upon assembly of octameric or 
decameric eIF2B across its symmetry interface. On the cis tetramer, eIF2a’s positively charged 
S-loop binds negatively charged and polar residues along the exposed surface of eIF2Bb. This 
binding site is consistent with yeast studies suggesting that mutations in this site compromise 
eIF2 binding (7). 
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Fig. 3 The bipartite basis of eIF2α recognition and assembly-stimulated activity. 
(A) Cryo-EM density for eIF2α bound to the regulatory subcomplex (α, β, δ, or RSC) of eIF2B. 
(B) Density and zoom-in detail of a cation-π interaction between eIF2Bδ and eIF2α. (C) Polar 
interactions between eIF2Bβ and the S-loop of eIF2α. (D and F) GEF activity of wild-type 
versus mutated eIF2B (βγδε) tetramers measured by BODIPY-labeled GDP fluorescence 
unquenching. (E and G) ISRIB-stabilized eIF2B (βγδε)2 octamers measured by BODIPY-labeled 
GDP fluorescence unquenching. A, Ala; N, Asn. 
 
 
Examination of the structure identified a potential hydrogen bond between eIF2Bb 
Asn132 and eIF2a Arg52 (Fig. 3C). We substituted Asn132 with aspartate (N132D), anticipating 
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that the introduced charge complementarity would enhance binding to eIF2a Arg52. When 
compared to wild-type eIF2B tetramers, eIF2B-bN132D tetramers and ISRIB-stabilized 
octamers indeed proved to be gain-of-function mutations, exhibiting enhanced GEF activity by a 
factor of ~2 [Fig. 3, F and G, and fig. S1D; eIF2B (bgde) bN132D kobs = 0.044 min−1 , eIF2B 
(bgde)2 bN132D kobs = 0.169 min−1 ]. This is consistent with eIF2B tetramers possessing 
reduced activity relative to assembled octameric or decameric holo-eIF2B. eIF2a binding in the 
cleft between tetramers further supports the notion that ISRIB enhances eIF2B’s GEF activity by 
promoting higher-order assembly. 
 
 
The structural basis of phosphoregulation by the ISR 
 
To understand how eIF2a phosphorylation on Ser51 transforms eIF2 from substrate to 
inhibitor, we coexpressed the isolated eIF2a subunit in E. coli with the kinase domain of PERK 
(doublestranded RNA–activated protein kinase-like ER kinase), an eIF2 kinase (fig. S1C). We 
incubated preassembled eIF2B decamers with an excess of eIF2a-P, followed by cross-linking 
and vitrification. Reconstruction of the eIF2B decamer adorned with two copies of eIF2a-P (Fig. 
4A, figs. S7 and S8, and tables S1 to S3) revealed eIF2a-P bridging the interface between eIF2Bd 
and eIF2Ba (Fig. 4A). 
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Fig. 4 The structural basis of phosphoregulation by the ISR. 
(A to C) Orthogonal views of a pair of Ser51-phosphorylated eIF2α subunits bound to the eIF2B 
decamer. (D) The productive binding mode of nonphosphorylated eIF2α. (E) The nonproductive 
and nonoverlapping binding mode of phosphorylated eIF2α. (F) Cryo-EM density of 
phosphorylated eIF2α bound to the regulatory subcomplex (α, β, δ) of eIF2B. (G) Zoom-in of the 
S-Loop cryo-EM density and model, placing the Ser51 phosphate moiety near eIF2α Arg53 and 
Arg63. 
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Intriguingly, we observed no overlap between the binding sites of nonphosphorylated 
eIF2a described above and eIF2a-P (Fig. 4, B and C). Density for both eIF2a Ser51-P and two 
arginines positioned ~4 Å away, eIF2a Arg53 and Arg63, were well resolved and suggestive of 
an electrostatic coordination responsible for phosphorylation-induced refolding of the S-loop 
(Fig. 4, F and G, fig. S8, and movie S1), as initially observed by Kashiwagi et al. (27). The 
phosphorylation-induced rearrangement also positions hydrophobic residues on eIF2a for 
potential interactions with hydrophobic residues on eIF2B (including eIF2a Ile55, Ile58, and 
Leu61 and eIF2Bd Leu314, Ala315, Ala318, and Phe322). This structural model agrees with 
analyses in yeast and mammalian systems. eIF2Ba is dispensable for viability in yeast, yet 
eIF2Ba deletion impairs phospho-inhibition of eIF2B, consistent with the subunit’s role in 
binding eIF2a-P (28). Point mutations with identical phenotypes cluster at the interface between 
eIF2Ba and eIF2Bd (e.g., eIF2Ba Phe239 and eIF2Bd Met506 and Pro508) (29, 30). eIF2Bd 
Leu314 complements the hydrophobic surface of the eIF2a S-loop that is exposed upon 
refolding, and mutation of Leu to Gln at the equivalent position in S. cerevisiae, L381Q, impairs 
the ISR in yeast (29). These data validate the phosphorylation-induced refolding and relocation 
of eIF2a-P observed here. 
 
Discussion 
 
Our analyses reveal the mechanistic basis of eIF2B’s nucleotide exchange activity and 
suggest how phosphorylation converts eIF2 from substrate to inhibitor. The nonphosphorylated 
form of eIF2 binds to a composite surface created only in the assembled decamer, allowing both 
the core and the flexibly attached HEAT domain of eIF2Be to engage its target in concert for 
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enhanced GEF activity. By contrast, eIF2a-P adopts a new conformation and suggests how the S- 
loop may become incompatible for binding to the site where nonphosphorylated eIF2a binds as a 
substrate (movie S1). Phosphorylation thus enables a distinct binding mode on the opposite side 
of eIF2B where eIF2a-P lies exiled at the interface of eIF2Ba and eIF2Bd. In eIF2a•P, the 
rearrangement of the S-loop derives from an intramolecular electrostatic interaction between 
Arg63 and Arg53 and the phosphate, which also exposes a hydrophobic surface upon 
phosphorylation-induced refolding. We surmise that this new binding mode is nonproductive for 
nucleotide exchange on eIF2-P and sequesters the catalytic domains into an inhibited state that 
prevents the catalytic moieties of eIF2Be from properly engaging in productive nucleotide 
exchange. 
 
 
Materials and Methods 
 
 
 
Purification of decameric eIF2B(αβγδε)2 
 
As previously described (17), pJT066, pJT073, and pJT074 were co-transformed into 
One Shot BL21 Star (DE3) chemically competent E. coli cells (Invitrogen) and grown in Luria 
broth containing ampicillin, kanamycin, and chloramphenicol at 37°C on an orbital shaker. When 
the culture reached an OD600 of ~0.6, the temperature was reduced to 16°C, and the culture was 
induced with 0.8 mM IPTG (Gold Biotechnology) and grown for 16 hours. Cells were harvested 
and lysed with an EmulsiFlex-C3 (Avestin) in a buffer containing 20 mM HEPES-KOH, pH 7.5, 
250 mM KCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 5 mM MgCl2, 15 mM imidazole, 
and complete EDTA-free protease inhibitor cocktail (Roche). The lysate was clarified at 30,000g 
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for 20 min at 4°C. Subsequent purification steps were conducted on the ÄKTA Pure (GE 
Healthcare) system at 4°C. The clarified lysate was loaded onto a HisTrap HP 5 ml, washed in 
binding buffer (20 mM HEPES-KOH, pH 7.5, 200 mM KCl, 1 mM TCEP, 5 mM MgCl2, and 15 
mM imidazole), and eluted with a linear gradient (75 ml) of 15 mM to 300 mM imidazole in the 
same buffer. The eIF2B fraction eluted from the HisTrap column at 80 mM imidazole. The 
eIF2B fraction was collected and loaded onto a 20 ml Mono Q HR16/10 column (GE 
Healthcare), washed in Buffer A (20 mM HEPES-KOH, pH 7.5, 200 mM KCl, 1 mM TCEP, and 
5 mM MgCl2) and eluted with a linear gradient (200 ml) of 200 mM to 500 mM KCl in the same 
buffer. The eIF2B fraction eluted off the Mono Q column at a conductivity of 46 mS/cm 
(corresponding to 390 mM KCl). Fractions were collected, concentrated with an Amicon Ultra- 
15 concentrator (EMD Millipore) with a 100,000-dalton molecular weight cutoff, and loaded 
onto a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with Buffer A. A typical 
preparation yielded approximately 0.5 mg of eIF2B(aβγδε)2 from a 1-liter culture. 
 
 
Purification of heterotrimeric human eIF2 
 
Human eIF2 was prepared from an established recombinant S. cerevisiae expression 
protocol (19). In brief, the yeast strain GP6452 (gift from the Pavitt lab, University of 
Manchester) containing yeast expression plasmids for human eIF2 subunits and a deletion of 
GCN2 encoding the only eIF2 kinase in yeast, was grown to saturation in synthetic complete 
media (Sunrise Science Products) with auxotrophic markers (-Trp, -Leu, -Ura) in 2% dextrose. 
The β and α subunits of eIF2 were tagged with His6 and FLAG epitopes, respectively. A 12-liter 
yeast culture was grown in rich expression media containing yeast extract, peptone, 2% 
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galactose, and 0.2% dextrose. Cells were harvested and resuspended in lysis buffer [100 mM 
Tris, pH 8.5, 300 mM KCl, 5 mM MgCl2, 0.1% NP-40, 5 mM imidazole, 10% glycerol (Thermo 
Fisher Scientific), 2 mM DTT, 1× protease inhibitor cocktail (Sigma Aldrich #11836170001), 1 
μg/ml each aprotinin (Sigma Aldrich), leupeptin (Sigma Aldrich), pepstatin A (Sigma Aldrich). 
Cells were lysed in liquid nitrogen using a steel blender. The lysate was centrifuged at 10,000g 
for 1 hour at 4°C. Subsequent purification steps were conducted on the ÄKTA Pure (GE 
Healthcare) system at 4°C. Lysate was applied to a 5-ml HisTrap Crude column (Thermo Fisher 
Scientific) equilibrated in buffer (100 mM HEPES, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.1% 
NP-40, 5% glycerol, 1 mM dithiothreitol, 0.5× protease inhibitor cocktail, 1 μg/ml each 
aprotinin, leupeptin, pepstatin A). eIF2 bound to the column, was washed with equilibration 
buffer and eluted using a 50 ml linear gradient of 5 mM to 500 mM imidazole. Eluted eIF2 was 
incubated with FLAG M2 magnetic affinity beads, washed with FLAG wash buffer (100 mM 
HEPES, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.1% NP-40, 5% glycerol, 1 mM TCEP, 1× 
protease inhibitor cocktail, 13 μg/ml each aprotinin, leupeptin, pepstatin A) and eluted with 
FLAG elution buffer [identical to FLAG wash buffer but also containing 3× FLAG peptide (100 
μg/ml, Sigma Aldrich)]. Concentration of purified protein was measured by BCA assay (Thermo 
Fisher Scientific # PI23225); protein was flash-frozen in liquid nitrogen and stored in elution 
buffer at –80° C. A typical preparation yielded 1 mg of eIF2 from a 12-liter culture. 
 
 
Purification of human eIF2α 
 
Human eIF2α was E. coli codon-optimized, synthesized and cloned into a pUC57 vector 
by GenScript Inc. PCR-amplified dsDNA fragments containing the eIF2α sequence were cloned 
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into a pET28a vector using an In-Fusion HD Cloning Kit (Takara Bio), resulting in the 
kanamycin-resistant expression plasmid, pAA007. pAA007 was co-transformed into One Shot 
BL21 Star (DE3) chemically competent E. coli cells (Invitrogen), along with the tetracycline- 
inducible, chloramphenicol-resistant plasmid, pG-Tf2, containing the chaperones groES, groEL, 
and tig (Takara Bio). Transformed cells were grown in Luria broth containing kanamycin and 
chloramphenicol at 37°C on an orbital shaker. When the culture reached an OD600 of ~0.2, 
1ng/mL tetracycline was added to induce expression of chaperones. At an OD600 of ~0.8, the 
temperature was reduced to 16°C, eIF2α expression was induced with 1 mM IPTG (Gold 
Biotechnology) and the culture was grown for 16 hours. Cells were harvested and lysed with an 
EmulsiFlex-C3 (Avestin) in a buffer containing 100 mM HEPES-KOH, pH 7.5, 300 mM KCl, 2 
mM dithiothreitol (DTT), 5 mM MgCl2, 5 mM imidazole, 10% glycerol, 0.1% NP-40, and 
complete EDTA-free protease inhibitor cocktail (Roche). The lysate was clarified at 10,000g for 
60 min at 4°C. Subsequent purification steps were conducted on the ÄKTA Pure (GE 
Healthcare) system at 4°C. The clarified lysate was loaded onto a 5-ml HisTrap FF Crude 
column (GE Healthcare), washed in a buffer containing 20 mM HEPES-KOH, pH 7.5, 100 mM 
KCl, 5% glycerol, 1 mM DTT, 5 mM MgCl2, 0.1% NP-40, and 20 mM imidazole, and eluted 
with 75-ml linear gradient of 20 to 500 mM imidazole. The eIF2α containing fractions were then 
collected and applied to a MonoS HR 10/10 (GE Healthcare) equilibrated in a buffer containing 
20 mM HEPES-KOH, pH 7.5, 100 mM KCl, 1 mM DTT, 5% glycerol, and 5 mM MgCl2. The 
column was washed in the same buffer and eluted with a 75-mL linear gradient of 100 mM to 1 
M KCl. eIF2α containing fractions were collected and concentrated with an Amicon Ultra-15 
concentrator (EMD Millipore) with a 30,000-dalton molecular mass cutoff and chromatographed 
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on a Superdex 75 10/300 GL (GE Healthcare) column equilibrated in a buffer containing 20 mM 
HEPES-KOH, pH 7.5, 100 mM KCl, 1 mM TCEP, 5 mM MgCl2, and 5% glycerol. A typical 
preparation yielded approximately 2 mg of eIF2α from a 1-liter culture. 
 
 
Purification of phosphorylated human eIF2α 
 
eIF2α was expressed and purified as above, but with the following modifications: One 
Shot BL21 Star (DE3) E. coli were co-transformed with pAA007, pG-Tf2, and a third plasmid 
expressing the kinase domain of PERK (PERK 4: PERKKD-pGEX4T-1, Addgene plasmid 
#21817 donated by Dr. David Ron) and a resistance marker towards ampicillin. Transformed 
bacteria were grown in Luria broth containing ampicillin, kanamycin, and chloramphenicol. For 
purification, 1x PhosSTOP (Roche) was added to the lysis and purification buffers. 
Phosphorylation was confirmed by Phos-Tag SDS-PAGE (Wako) as described previously (31), 
and by Western blot with an eIF2α S51 phosphorylation-specific antibody (Cell Signaling, 
#9721). 
 
 
Purification of tetrameric eIF2B(βγδε) 
 
Tetrameric eIF2B(βγδε) and tetrameric eIF2B(βγδε) mutant proteins were purified using 
the same protocol as described for the decamer with the exception that expression strains were 
cotransformed without the eIF2B a subunit expressing plasmid. A typical preparation yielded 
approximately 0.75 mg of eIF2B(βγδε) from a 1-liter culture. 
eIF2B(βγδε) tetramer with co-transformed plasmids: pJT073, pJT074 βN132D 
 
eIF2B(βγδε) tetramer with co-transformed plasmids: pAA012, pJT074 δR250A 
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eIF2B(βγδε) tetramer with co-transformed plasmids: pAA013, pJT074 δR250E 
eIF2B(βγδε) tetramer with co-transformed plasmids: pAA014, pJT074 
 
 
Cloning of mutant eIF2B expression plasmids 
 
Mutant eIF2B constructs were generated by site-directed mutagenesis on pJT073 for β 
and δ, and pJT066 for α, using the primer indicated and its reverse complement. 
βN132D (pAA012): 5′- 
CCACTACGCTCAGCTGCAGTCTGACATCATCGAAGCTATCAACG-3′ 
δR250A (pAA013): 5′- 
CCCCGCCGAACGAAGAACTGTCTGCTGACCTGGTTAACAAACTGAAACCG-3′ 
 
δR250E (pAA014): 5′- 
CCCCGCCGAACGAAGAACTGTCTGAGGACCTGGTTAACAAACTGAAACCG-3′ 
 
 
EM sample preparation and data collection for ISRIB-bound eIF2•eIF2B and eIF2α•eIF2B 
complexes 
Decameric eIF2B(αβγδε)2 + eIF2(αβγ) + ISRIB: eIF2B(αβγδε)2 was diluted to 800 nM 
eIF2B, eIF2 to 2 μM, and a stock solution of 200 μM ISRIB in N-methyl-2-pyrrolidone (NMP) 
was added to a final ISRIB concentration of 2 μM in a final solution containing 20 mM HEPES- 
KOH, pH 7.5, 100 mM KCl, 1 mM TCEP, 5 mM MgCl2, 0.1% NMP, and incubated on ice for 
10 min. An inter-amine bifunctional crosslinker (Pierce premium BS3, #PG82084) was then 
added at a concentration of 0.25mM, and the mixture was incubated on ice for 2 hours before 
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quenching with 10mM Tris HCl. Decameric eIF2B(αβγδε)2 + eIF2α(P): eIF2B(αβγδε)2 was 
diluted to 800 nM and eIF2α(P) to 2.4μM in a final solution containing 20 mM HEPES-KOH, 
pH 7.5, 100 mM KCl, 1 mM TCEP, 5mM MgCl2, 0.1% NMP, and incubated on ice for 10 min 
and cross-linked as described above. Each sample was applied to Quantifoil R 1.2/1.3 200 or 400 
Au mesh grids (Quantifoil, Germany). Quantifoil grids were used without glow discharging. 
Using a Vitrobot Mark IV at 4°C and 100% humidity with Whatman Filter Paper 1, 3.5 μl of 
sample was applied to the grid, incubated for an additional 10s, then blotted with 0 mm offset for 
~6 s and plunge-frozen in liquid ethane. Two data sets were collected. Both data sets were 
collected with on a 300 kV Titan Krios at UCSF using a K2 Summit detector operated in 
superresolution mode; 3233 images for eIF2P•eIF2B and 3947 images for eIF2•eIF2B were 
collected at a magnification of 29,000x (0.41Å per super-resolution pixel, binned by a factor of 2 
to 0.82Å for subsequent processing). Dose-fractionated stacks were collected according to the 
parameters in Table S1. 
 
 
Image analysis and 3D reconstruction 
 
All dose-fractionated image stacks were corrected for motion artifacts, 2× binned in the 
Fourier domain, and dose-weighted using MotionCor2 (32), resulting in one dose-weighted and 
one unweighted integrated image per stack with pixel sizes of 0.822 Å. The parameters of the 
contrast transfer function (CTF) were estimated using GCTF-v1.06 (33) and the motion- 
corrected but unweighted images; automated particle picking was done using Gautomatch-v0.53 
and averaged in 2D using Cryosparc v0.6.5 (34). For the 3D reconstruction, an ab initio 
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reconstruction was done without symmetry, followed by homogeneous refinement. High- 
resolution homogeneous refinement was then performed in cryoSPARC, using dynamic masks 
and imposed C2 symmetry for 2 eIF2 bound to eIF2B, C1 symmetry was used for 1 eIF2 bound 
to eIF2B. These maps were low-pass filtered and sharpened in cryoSPARC. For eIF2α-phospho 
bound to eIF2B, manual refinement with C2 symmetry and automated sharpening were 
performed in cisTEM (35). Molecular graphics and analyses were performed with the UCSF 
Chimera package. UCSF Chimera is developed by the Resource for Biocomputing, 
Visualization, and Informatics and supported by NIGMS P41-GM103311 (36). Accession 
numbers for the structures are as follows: EMD-0649, EMD-0651, EMD-0664 (density maps; 
Electron Microscopy Data Bank). 
 
 
Atomic modeling and validation 
 
For all models, previously determined structures of the human eIF2B complex [PDB: 
6CAJ (17)], human eIF2 alpha [PDBs: 1Q8K (20) and 1KL9 (21)], the C-terminal HEAT 
domain of eIF2B epsilon [PDB: 3JUI (26)], and mammalian eIF2 gamma [PDB: 5K0Y (37)] 
were used for initial atomic interpretation. The models were manually adjusted and rebuilt in 
Coot (38) and then refined in phenix.real_space_refine (39) using global minimization, 
morphing, secondary structure restraints, Ramachandran restraies, and local grid search. Then 
iterative cycles of manually rebuilding in Coot and phenix.real_space_refine with additionally B- 
factor refinement were performed. The final model statistics were tabulated using Molprobity 
(40) (Table S3). Map versus atomic model FSC plots were computed after masking using 
EMAN2 (41) and using calculated density maps from e2pdb2mrc.py with heteroatoms (ISRIB) 
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and per-residue B-factor weighting. Solvent accessible surfaces and buried surface areas were 
calculated from the atomic models using UCSF Chimera. Final atomic models have been 
deposited at the PDB with the following accession codes: 1 eIF2•eIF2B•ISRIB (6O81); 2 
eIF2•eIF2B•ISRIB (6O85); phosphorylated eIF2α•eIF2B (6O9Z). All structural figures were 
generated with UCSF Chimera (36) and BLENDER (http://www.blender.org). 
GDP exchange assay 
We modified the procedure to establish a loading assay for fluorescent GDP as described (1). 
Purified eIF2 (200 pmol) was incubated with a molar equivalent Bodipy-FL-GDP (Thermo 
Fisher Scientific) in assay buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 5 mM MgCl2, 1 mM 
TCEP, 0.1% NMP, and 1 mg/ml bovine serum albumin) to a volume of 18 μl in 384 square-well 
black-walled, clear-bottom polystyrene assay plates (Corning). The reaction was initiated by 
addition of 2 μl of buffer or purified wild-type and mutant eIF2B(βγδε) (2 pmol) under various 
conditions to compare nucleotide exchange rates. For comparison of tetramer or ISRIB- 
assembled octamer, eIF2B(βγδε) (2 pmol) was preincubated in 0.1% NMP and 2 mM ISRIB for 
15 min before 10-fold dilution into the final reaction. These concentrations of vehicle and ISRIB 
were used throughout unless otherwise specified. Fluorescence intensity for both loading and 
unloading assays was recorded every 10 seconds for 60 or 100 minutes using a TECAN M1000 
Pro plate reader (excitation wavelength: 495 nm, bandwidth 5 nm, emission wavelength: 512 nm, 
bandwidth: 5 nm). Data collected were fit with a first-order exponential equation. 
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Negative Stain collection and 2D Classification 
 
Decameric eIF2B(αβγδε)2 + eIF2(αβγ) + ISRIB: eIF2B(αβγδε)2 was diluted to 800 nM 
eIF2B, eIF2 to 2 μM, and a stock solution of 200 μM ISRIB in N-methyl-2-pyrrolidone (NMP) 
was added to a final ISRIB concentration of 2 μM in a final solution containing 20 mM HEPES- 
KOH, pH 7.5, 100 mM KCl, 1 mM TCEP, 5 mM MgCl2, 0.1% NMP, and incubated on ice for 
10 min. EM grids of negatively stained sample were prepared by applying 4 μL of sample to a 
400 mesh copper grid covered with continuous carbon film and stained with 2 % (w/v) uranyl 
formate, following the established procedure (42). Negative-stain EM grids were imaged on a 
FEI Tecnai T20 microscope (Thermo Fisher Scientific, US) operated at 200kV and equipped 
with a TVIPS TemCam F816 (8K 8K) scintillator based CMOS camera (TVIPS, Germany). 
Images were recorded at a nominal magnification of 50,000×, corresponding to a pixel size of 
 
1.57 Å at specimen level, and with a defocus set to 1.2 μm. 
23  
References 
 
1. H. P. Harding et al., Mol. Cell. 11, 619–33 (2003). 
 
 
2. L. R. Palam, T. D. Baird, R. C. Wek, J. Biol. Chem. 286, 10939–10949 (2011). 
 
 
3. K. M. Vattem, R. C. Wek, Proc. Natl. Acad. Sci. 101, 11269–11274 (2004). 
 
 
4. K. Kashiwagi et al., Nature. 531, 122–125 (2016). 
 
 
5. Y. Gordiyenko et al., Nat. Commun. 5, 3902 (2014). 
 
 
6. B. Kuhle, N. K. Eulig, R. Ficner, Nucleic Acids Res. 43, gkv930 (2015). 
 
 
7. K. Dev et al., Mol. Cell. Biol. 30, 5218–33 (2010). 
 
 
8. G. D. Pavitt, K. V Ramaiah, S. R. Kimball, A. G. Hinnebusch, Genes Dev. 12, 
514–26 (1998). 
9. S. R. Kimball, J. R. Fabian, G. D. Pavitt, A. G. Hinnebusch, L. S. Jefferson, J. 
Biol. Chem. 273, 12841–5 (1998). 
 
10. T. Krishnamoorthy, G. D. Pavitt, F. Zhang, T. E. Dever, A. G. Hinnebusch, Mol. 
 
Cell. Biol. 21, 5018–5030 (2001). 
24  
11. C. Sidrauski et al., Elife. 2 e00498 (2013). 
 
 
12. C. Sidrauski et al., Elife. 4 e07314 (2015). 
 
 
13. Y. Sekine et al., Science. 348, 1027–30 (2015). 
 
14. A. Chou et al., Proc. Natl. Acad. Sci. U. S. A. 114, E6420–E6426 (2017). 
 
 
15. M. Halliday et al., Cell Death Dis. 6, e1672 (2015). 
 
 
16. Y. L. Wong et al., bioRxiv, 462820 (2018). 
 
 
17. J. C. Tsai et al., Science. 359, eaaq0939 (2018). 
 
 
18. A. F. Zyryanova et al., Science. 359, 1533–1536 (2018). 
 
 
19. R. A. de Almeida et al., PLoS One. 8, e53958 (2013). 
 
 
20. T. Ito, A. Marintchev, G. Wagner, Structure. 12, 1693–1704 (2004). 
 
 
21. S. Dhaliwal, D. W. Hoffman, J. Mol. Biol. 334, 187–195 (2003). 
 
 
22. B. Eliseev et al., Nucleic Acids Res. 46, 2678–2689 (2018). 
25  
23. V. Beilsten-Edmands et al., Cell Discov., 1 15020 (2015). 
 
 
24. E. Dubiez, A. Aleksandrov, C. Lazennec-Schurdevin, Y. Mechulam, E. Schmitt, 
 
Nucleic Acids Res. 43, 2946–2957 (2015). 
 
25. T. Boesen, S. S. Mohammad, G. D. Pavitt, G. R. Andersen, J. Biol. Chem. 279, 
10584–10592 (2004). 
 
26. J. Wei et al., Protein Cell. 1, 595–603 (2010). 
 
 
27. R. Elsby et al., J. Virol. 85, 9716–25 (2011). 
 
28. G. D. Pavitt, W. Yang, A. G. Hinnebusch, Mol. Cell. Biol. 17, 1298–313 (1997). 
 
 
29. C. R. Vazquez de Aldana, A. G. Hinnebusch, Mol. Cell. Biol. 14, 3208–22 (1994). 
 
 
30. A. Crespillo-Casado et al., J. Biol. Chem. 293, 7766–7776 (2018). 
 
31. S. Q. Zheng et al., Nat. Methods. 14, 331–332 (2017). 
 
32. K. Zhang, J. Struct. Biol. 193, 1–12 (2016). 
 
33. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, Nat. Methods. 14, 290– 
296 (2017). 
34. T. Grant, A. Rohou, N. Grigorieff, Elife. 7 (2018), doi:10.7554/eLife.35383. 
26  
35. E. F. Pettersen et al., J. Comput. Chem. 25, 1605–1612 (2004). 
 
36. A. Simonetti et al., Mol. Cell. 63, 206–217 (2016). 
 
 
37. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Acta Crystallogr. Sect. D Biol. 
 
Crystallogr. 66, 486–501 (2010). 
 
 
38. P. D. Adams et al., Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213–221 
(2010). 
39. V. B. Chen et al., Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 12–21 (2010). 
 
 
40. S. J. Ludtke, Methods Enzymol. 579, 159–89 (2016). 
27  
Publishing Agreement 
It is the policy of the University to encourage the distribution of all theses, dissertations, and manuscripts. 
Copies of all UCSF theses, dissertations, and manuscripts will be routed to the library via the Graduate 
Division. The library will make all theses, dissertations, and manuscripts accessible to the public and will 
preserve these to the best of their abilities, in perpetuity. 
I hereby grant permission to the Graduate Division of the University of California, San Francisco to release 
copies of my thesis, dissertation, or manuscript to the Campus Library to provide access and preservation, in 
whole or in part, in perpetuity. 
Author Signature  Date _09/12/2019  
